Lafora Disease: A Case Report
PDF
Cite
Share
Request
Case Report
VOLUME: 22 ISSUE: 1
P: 32 - 36
April 2016

Lafora Disease: A Case Report

Arch Epilepsy 2016;22(1):32-36
1. Selcuk University, Meram School Of Medicine, Neurology Department, Konya
2. Selcuk University, Meram School Of Medicine, Pathology Department, Konya
3. Selcuk University, Meram School Of Medicine, Plastic And Reconstructive Surgery Department, Konya
No information available.
No information available
Received Date: 03.06.2015
Accepted Date: 29.07.2015
PDF
Cite
Share
Request

ABSTRACT

Lafora disease (LD) is a progressive myoclonus epilepsy with autosomal recessive inheritance. Clinical course is progressive and includes myoclonic, cerebellar, and extrapyramidal signs, generalized tonic-clonic seizures, and cognitive decline. Valproic acid, zonisamide, levetiracetam, clonazepam, and piracetam are among the treatment options. Carbamazepine (CBZ), oxcarbazepine, phenytoin, and lamotrigine (LM) should be avoided to prevent worsening of symptoms. Though evidence is limited, perampanel is the only drug to achieve sustained improvement in frequency of seizures, and effective control of neurological and cognitive decline in patients with LD. Described in the present report is a case of typical LD with clinical worsening on CBZ and LM treatment. Electroencephalographic and pathologic findings are reported.

Keywords:
Lafora disease, perampanel, progressive myoclonic epilepsy